OSA is the most common type of sleep-disordered breathing (SDB). In surgical patients, the prevalence of OSA by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes or polysomnography (PSG) is 7% to 10%, 1, 2 with a large proportion remaining undiagnosed. 3 Patients with OSA may have an increased sensitivity to anesthetics or opioids, [4] [5] [6] greater upper airway collapsibility, 7, 8 and increased risk of postoperative complications. 2, 9, 10 CPAP therapy is the mainstay treatment for patients with moderate-to-severe OSA, but its adherence remains a challenge. [11] [12] [13] For patients with newly diagnosed untreated OSA or suspected OSA, surgical timing may not allow adequate time to establish diagnosis and initiate treatment. 14 For surgical patients with OSA, supplemental oxygen may be more acceptable than CPAP therapy, but three clinical concerns exist. First, hypoxemia may play a critical role in respiratory arousal in surgical patients with OSA. When supplemental oxygen abolishes hypoxemia, the apnea duration may increase, [15] [16] [17] causing hypoventilation as evidenced by hypercarbia, leading to possible life-threatening respiratory depression. Second, postoperative opioids may depress respiration centrally and impair the arousal threshold causing arousal failure, possibly leading to sporadic case of death. 18 The third concern is that supplemental oxygen may mask the ability of oximetry to detect abnormalities in the level of ventilation. 19, 20 To date, no published study has investigated the effect of postoperative supplemental oxygen on patients with newly diagnosed untreated OSA. The objective of this randomized controlled trial (RCT) was to investigate the effect of postoperative supplemental oxygen on SaO 2 , sleep respiratory events, and CO 2 level in patients with untreated OSA. We hypothesize that postoperative supplemental oxygen would improve oxygenation in patients with OSA, without significantly increasing the duration of sleep apneic episodes and arterial CO 2 tension.
Materials and Methods

Trial Design
This prospective RCT was registered at ClinicalTrials.gov (No. NCT01552304). The study was completed at Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada, from February 2012 to December 2015, with Institutional Review Board approval (No. UHN 11-0302-AE). Supplemental oxygen at 3 L/min via nasal prongs was the trial intervention. The primary outcomes were PSG parameters measuring arterial oxygen saturation (SaO 2 ), sleep respiratory events (frequency and duration), and PCO 2 measured by transcutaneous CO 2 monitor (P tc CO 2 ) on postoperative night 3. Approximately 60% and 7% of patients at our institution receive supplemental oxygen on postoperative nights 1 and 3, respectively. 21 To minimize the cross contamination of the control group, we chose night 3 as the time point for outcome measurement.
Eligibility and Trial Procedures
The inclusion criteria were as follows: (1) elective surgery with $ 3 nights stay, (2) age 18 to 80 years, and (3) patients at high risk of OSA (STOP-Bang questionnaire score $ 3) 22 Eligible surgical patients attending preoperative clinic were consented (Fig 1) . Recruited patients completed a preoperative PSG at home with a level II 10-channel portable device (Embletta x100; Embla) as previously described. 23 The PSG recording montage consisted of two electroenephalographic channels (C3 and C4), left or right electroculogram, chin muscle electromyograms, nasal cannula (pressure), thoracic and abdominal respiratory effort bands, body position sensor, and pulse oximetry. This montage allows us to measure the parameters on sleep architecture, sleep respiratory events, arousal events, sleep positon, oxygen desaturation, and heart rate. The PSG recordings were manually scored by a PSG technologist according to the American Academy of Sleep Medicine 2007 criteria. 24 Apnea was defined as $ 90% drop in air flow from baseline for $ 10 seconds. Apneic episodes were further classified as obstructive, central, or mixed apneas. Hypopnea was defined as $ 50% reduction in air flow for $ 10 seconds and $ 3% decrease in SaO 2 or associated with arousal. Oxygen desaturation index (ODI) is the average number of episodes of desaturation $ 4% and lasting $ 10 seconds per hour of sleep.
Patients with an apnea hypopnea index (AHI) $ 5 events per hour were equally randomized into the oxygen (O 2 ) group or control group. Allocation was made via a computerized block randomization by a research analyst not involved in the study implementation. The research coordinator, the PSG technologist, and the chart reviewers were blinded to the group allocation. Patients in the control group were managed by anesthesiologists and surgeons as per routine practice, including supplemental oxygen or CPAP therapy as clinically indicated. In the O 2 group, patients received 3 L/min nasal supplemental oxygen for 3 postoperative nights (nights 1-3) in addition to the routine care. Postoperative night 1 was defined as the night of surgery.
The study patients completed PSG on night 3. P tc CO 2 was monitored with a CO 2 monitor (TCM400; Radiometer Medical ApS) via a probe attached to the inner side of the patient's arm on nights 1 to 3. A related model capable of monitoring both P tc CO 2 and SaO 2 (TOSCA 500 instrument; Radiometer Medical ApS) has demonstrated a stable long-term (6 hours) measurement of P tc CO 2 without relevant drift. 25 Repeated calibration against gas with a known CO 2 concentration, autocalibration, and membrane replacement was performed according to the manufacturer's recommendations. A total of 255 CO 2 monitorings were done, and 18 (7.6%) failed (recording < 2 hours).
Recording between 9 PM and 6 AM was selected. Unreliable data with extremely low readings (P tc CO 2 < 20 mm Hg) were removed. The parameters of mean, median, highest P tc CO 2 , and time percent with P tc CO 2 > 45 and 55 mm Hg were extracted from P tc CO 2 recordings. Patients were visited daily by a research coordinator for assistance with the devices and data collection.
Statistical Analysis
Because, to our knowledge, there are no published studies with a similar design, the sample size estimation was based on two studies comparing supplemental oxygen and CPAP in nonsurgical patients with OSA that used cumulative time percentage with SaO 2 < 90% (CT90). 26, 27 Based on the average CT90 of these two studies (1.8% in O 2 group vs 4.8% in control group) and the larger SD (4.5%), assuming a two-tailed twosample t test, a error ¼ 0.025, power ¼ 0.85, and equal allocation into two groups, the estimated total sample size was 100. Accounting for a 20% dropout rate, the number of patients randomized would be 100 Â 1.20 ¼ 120 patients (60 per group).
Data were entered into a specifically designed Microsoft Access database (Microsoft) and checked for possible errors. SAS 9.3 for Windows (SAS Institute) was used for data analysis. Descriptive statistics were completed on the clinical data and the SDB parameters on the preoperative baseline PSG. An intention-to-treat analysis was first carried out according to randomization (O 2 group vs control group). Missing PSG data (control group: n ¼ 7; O 2 group: n ¼ 13) on night 3 were imputed with preoperative value (last observation carried forward). Because oxygen is often prescribed after surgery, supplementary analyses were carried out according to the dropout and actual use of oxygen (per protocol). In per protocol analyses, regardless of randomization, patients receiving oxygen on night 3 were grouped into the Oxygen group, and those not receiving oxygen were grouped into the No-Oxygen group.
Continuous variables with normal distribution are presented as mean AE SD, and comparison between groups was assessed using an independent two-sample t test. Variables with skewed distribution are presented as median (25th-75th percentile), and comparison between groups was performed with the nonparametric MannWhitney U test. Categorical data are presented as frequency and percentage, and c 2 test was used for statistical assessment. The P values for multiple comparisons were adjusted using the HolmBonferroni method. The potential risk factors for postoperative hypercapnia were evaluated by univariate logistic regression.
Results
Study Population and Baseline Data
The recruitment and follow-up of patients are shown in Figure 1 . There were 123 patients with AHI $ 5 events per hour randomized to the O 2 group (n ¼ 62) or control group (n ¼ 61). The demographic data, average AHI, American Society of Anesthesiologists physical status, comorbidities, postoperative 72-hour opioids requirement, and type of surgery and anesthesia were similar between the groups ( journal.publications.chestnet.org completed PSG on night 3, respectively (Fig 1) . In the O 2 group, one patient with a history of emphysema was excluded because of intubation as a result of hypercarbia and desaturation. The patient was extubated in the ICU 4 hours later. In patients receiving general surgery, four (6.5%) patients in the O 2 group underwent upper abdominal procedures (gastric bypass: n ¼ 3; gastrectomy: n ¼ 1), and three (4.9%) patients in the control group received upper abdominal procedures (gastric bypass: n ¼2; gastroplasty: n ¼ 1).
Oxygen Therapy
In the control group, despite randomization to no supplemental oxygen, 11 (20%) of the patients received 3 L/min supplemental oxygen with nasal prongs on night 3, as ordered by the health-care teams. In the control group, more patients with severe OSA received supplemental oxygen on postoperative night 3: mild SDB: 10.3% (3/29); moderate SDB: 13.3% (2/15); and severe SDB: 35.3% (6/17). The difference was not significant (P ¼ .090). (20) 16 (26) Gastroesophageal reflux 15 (25) 17 ( Nine patients in the control group also received supplemental oxygen during the daytime. Of them, 7 patients experienced desaturation because of bronchospasm (n ¼ 2), atelectasis (n ¼ 1), and undefined reasons (n ¼ 4); other patients experienced hypotension, hypertension, inadequate pain control, and somnolence. In the O 2 group, all patients received 3 L/min supplemental oxygen on night 3. No patient received CPAP therapy.
Effect of Oxygen on SaO 2
There was no difference in the baseline variables regarding oxygen saturation (average SaO 2 , lowest Sao 2 , CT90, and ODI) on the preoperative PSG either based on the intention-to-treat (Fig 2A, Table 2 ) or per protocol (as treated) analysis (Fig 2C, Table 3 ). On night 3, supplemental oxygen significantly improved oxygen saturation per intention-to-treat (Fig 2B, Table 2 ) and per protocol analyses ( Fig 2D, Table 3 ).
Effect of Oxygen on SDB
The baseline parameters on the preoperative PSG were similar between the O 2 and control groups (intentionto-treat) ( Fig 3A, Table 2 ) or between the Oxygen and No-Oxygen groups (per protocol analysis) ( , the line inside the box represents the median, the upper whisker is drawn from the upper edge of the box to the largest value within 1.5Â IQR, the lower whisker is drawn from the lower edge of box to the smallest value within 1.5Â IQR, and colorful dot and triangles indicate the values outside 1.5Â IQR. ASaO2 ¼ average pulse oxygen saturation (%); CT90 ¼ cumulative time percentage with SaO 2 < 90% (%); LSaO2 ¼ lowest pulse oxygen saturation (%); ODI ¼ oxygen desaturation index (events/h); WASaO2 ¼ wake average pulse oxygen saturation (%). *Adjusted P < .05 vs control or nonoxygen group.
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Mixed apnea index (Fig 3D) . In the No-Oxygen group, AHI increased from a median 13.8 (25th-75th percentile, 9.1-28.1) preoperatively to 17.1 (25th-75th percentile, 10.2-58.4) events per hour on night 3 (P ¼ .132) (Fig 3D) . In all patients receiving oxygen supplementation on postoperative night 3, patients with severe SDB vs mild SDB had significantly more AHI reduction (median, À31.0; 25th-75th percentile, À41.4 to À11.1 vs median, À5.3; 25th-75th percentile, À7.8 to 5.7 events per hour, respectively; P < .05).
No difference occurred in the sleep architecture between groups on preoperative baseline or night 3, either based on intention-to-treat or per protocol analysis (data not shown). 
Effect of Oxygen on P tc CO 2
The P tc CO 2 data on nights 1 through 3, based on intention-to-treat analysis, were summarized in Figure 4A and Table 4 . No difference was found between the control and O 2 groups in the average P tc CO 2 , median P tc CO 2 , number of patients with P tc CO 2 > 45 mm Hg or P tc CO 2 > 55 mm Hg, and the overnight cumulated time percentage with P tc CO 2 > 45 mm Hg or time percentage with P tc CO 2 $ 55 mm Hg (P tc CO 2 -CT55). The per protocol analysis did not show a difference either (Fig 4B) . However, a significant increase in P tc CO 2 was found in a small number of patients. A total of 14 (11.4%) patients had P tc CO 2 -CT55 $ 10% on postoperative night 1, 2, or 3 (Table 5 ). Most (93%; 13/14) were receiving oxygen therapy at the time of elevated CO 2 levels (control group: n ¼ 7; O 2 group: n ¼ 6). A large number (9/14) experienced the highest P tc CO 2 on night 1. Only one patient had the comorbidity of COPD. Two patients experienced prolonged overnight desaturation (SaO 2 < 90%). No patient had life-threatening complications.
To explore the potential risk factors for postoperative hypercapnia, we used P tc CO 2 
Discussion
To date, this is the first RCT on postoperative supplemental oxygen in surgical patients with newly diagnosed untreated OSA. Postoperative supplemental oxygen was found to improve oxygenation and decreased AHI without significantly increasing the apnea-hypopnea event duration or P tc CO 2 level. Eleven percent of patients had significant CO 2 retention while receiving supplemental oxygen.
Hypoxemia is an immediate consequence of apneic and hypopnea events. OSA-related complications could be induced by hypoxemia. 28 Our data from the intentionto-treat analysis show that supplemental oxygen significantly decreased AHI, NREM-AHI, and hypopnea index. The results from the per protocol (as treated) analysis show that supplemental oxygen not only decreased AHI, NREM-AHI, and hypopnea index but also decreased REM-AHI, central apnea index, and longest apnea-hypopnea event duration. Because 20% of patients in the control group received supplemental oxygen, results from the per protocol analysis would better reflect the effects of supplemental oxygen on sleep respiratory events. In previous studies of nonsurgical patients with OSA, the effect of supplemental oxygen on sleep respiratory events was inconsistent. Compared with breathing room air, breathing oxygen reduced the frequency of apnea, which may be related to increased PaCO 2 , stimulating ventilation during sleep. 15 In contrast, other studies found that the length of apnea was increased by breathing oxygen, 29 and AHI was not decreased. 17, 30 In peritoneal dialysis patients with OSA, nocturnal oxygen therapy decreased hypopnea and central apnea. 31 Oxygen effectively reduced central sleep apnea in patients with eucapnia, but obstructive and mixed apneas were unaffected by oxygen. 32 In this study, the decrease in AHI was mainly caused by a drop in hypopnea index and, to a minor degree, central apnea. Because hypopnea index was not separated into central or obstructive hypopnea component, the contributing role of each cannot be determined. Another possible mechanism for the reduction of hypopnea events is caused by improvement of oxygenation by supplemental oxygen, rendering less events meeting hypopnea criterion (Tables 2, 3 ).
The discrepancy in the effect of supplemental oxygen on sleep respiratory events both between subjects and between studies may be caused by the various pathophysiologic mechanisms causing OSA. 33 The mechanisms include the following: (1) an anatomically collapsible upper airway characterized by a high passive critical closing pressure 34 ; (2) inadequate response of the upper airway dilator muscles during sleep characterized by minimal increase in electromyographic activity in response to progressive negative pharyngeal pressure 35, 36 ; (3) waking up prematurely to airway narrowing characterized by a low respiratory arousal threshold 37, 38 ; and (4) an oversensitive ventilatory 
Data are presented as No. (%), median (25th-75th percentile), mean AE SD, or as otherwise indicated. P tc CO 2 ¼ PCO 2 measured by transcutaneous CO 2 monitor. control system characterized by high loop gain. 38 With the different pathophysiologic mechanisms, strategies to target treatment would be more effective.
Supplemental oxygen was shown to decrease AHI in patients with high loop gain, but not in patients with low loop gain. 39 The high loop gain in patients with OSA is induced by intermittent hypoxia and can be reversed by preventing hypoxia with supplemental oxygen or CPAP therapy. 40, 41 Supplemental oxygen increases ventilatory stability in patients with ventilatory instability (high loop gain). 39 Further work is needed to determine whether patients with OSA caused by other pathophysiologic processes would benefit from supplemental oxygen.
One concern for surgical patients with OSA is that supplemental oxygen could lead to longer apneas events with associated hypercapnia and sustained hypoventilation. In previous studies, the duration of apnea was found increased by supplemental oxygen. 16, 29 In a study of 28 asymptomatic men with heavy snoring, the frequency of apneas was not decreased, but the length of apnea was increased by supplemental oxygen. 29 In another study of 20 obese men with sleep apnea and COPD, mean event duration and end apneic PCO 2 were increased by supplemental oxygen (4 L/min). 16 In this study, we found that the duration of the longest apnea-hypopnea events was shortened by supplemental oxygen. There are two possible reasons for our finding of shortening of longest apnea-hypopnea event duration. The first reason is because of the difference in study populations. In our study, only 3% of patients had COPD, whereas in the Alford et al study, 16 all patients had COPD. We also excluded patients with possible OHS by not recruiting patients with HCO 3 $ 30 mEq/L. Patients with COPD and OHS are more likely to suffer from respiratory suppression and CO 2 retention with supplemental oxygen. 42 The second reason is the definition of event duration. In our study, the duration was calculated based on both apnea and hypopnea events. Supplemental oxygen eliminated some of the hypopnea events by making them not meeting hypopnea criteria because of improved oxygen saturation, possibly leading to shortened duration of apnea-hypopnea events.
OHS is present in 10% to 20% of patients with OSA. 43 Supplemental oxygen may worsen hypercapnia in patients with OHS. 42 To avoid recruiting patients with OHS, patients with serum HCO 3 -levels > 30 mmol/L were excluded. A low flow (3 L/min) of oxygen was used. These factors may contribute to no overall difference in P tc CO 2 metrics between groups on nights 1 through 3, either on intention-to-treat or per protocol analysis. A small number (11.4%) of patients experienced substantial CO 2 retention, especially those receiving oxygen on night 1. When opioids or hypnotics are used, administration of oxygen may cause significant CO 2 retention in a small number of patients. 20 To define the risk factors for postoperative hypercapnia, we need a study with a larger sample size.
Increased inspired oxygen may result in greater opioid-induced respiratory depression. 20 When supplemental oxygen is given, it may mask the ability of oximetry to detect abnormalities in the level of ventilation. 19, 20 Additional methods for detecting hypoventilation, such as continuous measurement of respiratory rate and end-tidal CO 2 monitoring, may be needed.
A limitation of this study is cross contamination. To ensure the safety of the participants, the perioperative care team could order oxygen or CPAP if deemed clinically necessary. Although no CPAP therapy was prescribed, a high percentage of patients in the control group received postoperative supplemental oxygen. This may interfere with the interpretation of the results. To minimize the effect of cross contamination, outcomes were measured on night 3 with less patients in the control group receiving oxygen, and data were subjected to per protocol (as treated) analysis to delineate the true effect of oxygen therapy. Another limitation is that the amplitude of postoperative change in P tc CO 2 could not be determined because of the lack of preoperative baseline data of P tc CO 2 . This may have led to an underestimation of the true P tc CO 2 changes with oxygen. Finally, the results are not generalizable to patients with OHS because of the exclusion of patients with serum HCO 3 -> 30 mmol/L.
In conclusion, postoperative supplemental oxygen improved oxygenation in surgical patients with OSA. Supplemental oxygen decreased AHI, hypopnea index, and central apnea index and shortened the longest apnea-hypopnea event duration. Although no overall difference was found between groups in P tc CO 2 level, a significant increase of P tc CO 2 was found in 11.4% of patients, especially those receiving oxygen on postoperative night 1. Postoperative supplemental oxygen could be used as an alternative therapy for patients with OSA not adherent to CPAP, newly diagnosed patients without adequate time to initiate CPAP therapy, or patients with suspected OSA. Additional monitoring of respiratory rate or P tc CO 2 , especially on postoperative night 1, is recommended. Further work is needed to identify OSA phenotypes which would benefit from postoperative supplemental oxygen and to identify which patients should be monitored for hypoventilation with respiratory rate or P tc CO 2 .
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